Perspectives on the use of gene therapy for chronic joint diseases

Steven C. Ghivizzani, Elvire Gouze, Jean Noel Gouze, Jesse D. Kay, Marsha L. Bush, Rachael S. Watson, Padraic P. Levings, David M. Nickerson, Patrick T. Colahan, Paul D. Robbins, Christopher H Evans

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Advances in molecular and cellular biology have identified a wide variety of proteins including targeted cytokine inhibitors, immunomodulatory proteins, cytotoxic mediators, angiogenesis inhibitors, and intracellular signalling molecules that could be of great benefit in the treatment of chronic joint diseases, such as osteo- and rheumatoid arthritis. Unfortunately, protein-based drugs are difficult to administer effectively. They have a high rate of turnover, requiring frequent readministration, and exposure in non-diseased tissue can lead to serious side effects. Gene transfer technologies offer methods to enhance the efficacy of protein-based therapies, enabling the body to produce these molecules locally at elevated levels for extended periods. The proof of concept of gene therapies for arthritis has been exhaustively demonstrated in multiple laboratories and in numerous animal models. This review attempts to condense these studies and to discuss the relative benefits and limitations of the methods proposed and to discuss the challenges toward translating these technologies into clinical realities.

Original languageEnglish (US)
Pages (from-to)273-286
Number of pages14
JournalCurrent Gene Therapy
Volume8
Issue number4
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Joint Diseases
Genetic Therapy
Chronic Disease
Proteins
Technology Transfer
Angiogenesis Inhibitors
Arthritis
Cell Biology
Molecular Biology
Rheumatoid Arthritis
Animal Models
Cytokines
Technology
Therapeutics
Pharmaceutical Preparations
Genes

Keywords

  • Adeno-associated virus
  • Adenovirus
  • Arthritis
  • Gene therapy
  • Interleukin-1
  • Lentivirus
  • Osteoarthritis
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery

Cite this

Ghivizzani, S. C., Gouze, E., Gouze, J. N., Kay, J. D., Bush, M. L., Watson, R. S., ... Evans, C. H. (2008). Perspectives on the use of gene therapy for chronic joint diseases. Current Gene Therapy, 8(4), 273-286. https://doi.org/10.2174/156652308785160638

Perspectives on the use of gene therapy for chronic joint diseases. / Ghivizzani, Steven C.; Gouze, Elvire; Gouze, Jean Noel; Kay, Jesse D.; Bush, Marsha L.; Watson, Rachael S.; Levings, Padraic P.; Nickerson, David M.; Colahan, Patrick T.; Robbins, Paul D.; Evans, Christopher H.

In: Current Gene Therapy, Vol. 8, No. 4, 2008, p. 273-286.

Research output: Contribution to journalArticle

Ghivizzani, SC, Gouze, E, Gouze, JN, Kay, JD, Bush, ML, Watson, RS, Levings, PP, Nickerson, DM, Colahan, PT, Robbins, PD & Evans, CH 2008, 'Perspectives on the use of gene therapy for chronic joint diseases', Current Gene Therapy, vol. 8, no. 4, pp. 273-286. https://doi.org/10.2174/156652308785160638
Ghivizzani SC, Gouze E, Gouze JN, Kay JD, Bush ML, Watson RS et al. Perspectives on the use of gene therapy for chronic joint diseases. Current Gene Therapy. 2008;8(4):273-286. https://doi.org/10.2174/156652308785160638
Ghivizzani, Steven C. ; Gouze, Elvire ; Gouze, Jean Noel ; Kay, Jesse D. ; Bush, Marsha L. ; Watson, Rachael S. ; Levings, Padraic P. ; Nickerson, David M. ; Colahan, Patrick T. ; Robbins, Paul D. ; Evans, Christopher H. / Perspectives on the use of gene therapy for chronic joint diseases. In: Current Gene Therapy. 2008 ; Vol. 8, No. 4. pp. 273-286.
@article{4c11f367f14f4726ad6ba932a93234ec,
title = "Perspectives on the use of gene therapy for chronic joint diseases",
abstract = "Advances in molecular and cellular biology have identified a wide variety of proteins including targeted cytokine inhibitors, immunomodulatory proteins, cytotoxic mediators, angiogenesis inhibitors, and intracellular signalling molecules that could be of great benefit in the treatment of chronic joint diseases, such as osteo- and rheumatoid arthritis. Unfortunately, protein-based drugs are difficult to administer effectively. They have a high rate of turnover, requiring frequent readministration, and exposure in non-diseased tissue can lead to serious side effects. Gene transfer technologies offer methods to enhance the efficacy of protein-based therapies, enabling the body to produce these molecules locally at elevated levels for extended periods. The proof of concept of gene therapies for arthritis has been exhaustively demonstrated in multiple laboratories and in numerous animal models. This review attempts to condense these studies and to discuss the relative benefits and limitations of the methods proposed and to discuss the challenges toward translating these technologies into clinical realities.",
keywords = "Adeno-associated virus, Adenovirus, Arthritis, Gene therapy, Interleukin-1, Lentivirus, Osteoarthritis, Tumor necrosis factor",
author = "Ghivizzani, {Steven C.} and Elvire Gouze and Gouze, {Jean Noel} and Kay, {Jesse D.} and Bush, {Marsha L.} and Watson, {Rachael S.} and Levings, {Padraic P.} and Nickerson, {David M.} and Colahan, {Patrick T.} and Robbins, {Paul D.} and Evans, {Christopher H}",
year = "2008",
doi = "10.2174/156652308785160638",
language = "English (US)",
volume = "8",
pages = "273--286",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Perspectives on the use of gene therapy for chronic joint diseases

AU - Ghivizzani, Steven C.

AU - Gouze, Elvire

AU - Gouze, Jean Noel

AU - Kay, Jesse D.

AU - Bush, Marsha L.

AU - Watson, Rachael S.

AU - Levings, Padraic P.

AU - Nickerson, David M.

AU - Colahan, Patrick T.

AU - Robbins, Paul D.

AU - Evans, Christopher H

PY - 2008

Y1 - 2008

N2 - Advances in molecular and cellular biology have identified a wide variety of proteins including targeted cytokine inhibitors, immunomodulatory proteins, cytotoxic mediators, angiogenesis inhibitors, and intracellular signalling molecules that could be of great benefit in the treatment of chronic joint diseases, such as osteo- and rheumatoid arthritis. Unfortunately, protein-based drugs are difficult to administer effectively. They have a high rate of turnover, requiring frequent readministration, and exposure in non-diseased tissue can lead to serious side effects. Gene transfer technologies offer methods to enhance the efficacy of protein-based therapies, enabling the body to produce these molecules locally at elevated levels for extended periods. The proof of concept of gene therapies for arthritis has been exhaustively demonstrated in multiple laboratories and in numerous animal models. This review attempts to condense these studies and to discuss the relative benefits and limitations of the methods proposed and to discuss the challenges toward translating these technologies into clinical realities.

AB - Advances in molecular and cellular biology have identified a wide variety of proteins including targeted cytokine inhibitors, immunomodulatory proteins, cytotoxic mediators, angiogenesis inhibitors, and intracellular signalling molecules that could be of great benefit in the treatment of chronic joint diseases, such as osteo- and rheumatoid arthritis. Unfortunately, protein-based drugs are difficult to administer effectively. They have a high rate of turnover, requiring frequent readministration, and exposure in non-diseased tissue can lead to serious side effects. Gene transfer technologies offer methods to enhance the efficacy of protein-based therapies, enabling the body to produce these molecules locally at elevated levels for extended periods. The proof of concept of gene therapies for arthritis has been exhaustively demonstrated in multiple laboratories and in numerous animal models. This review attempts to condense these studies and to discuss the relative benefits and limitations of the methods proposed and to discuss the challenges toward translating these technologies into clinical realities.

KW - Adeno-associated virus

KW - Adenovirus

KW - Arthritis

KW - Gene therapy

KW - Interleukin-1

KW - Lentivirus

KW - Osteoarthritis

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=54749118186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54749118186&partnerID=8YFLogxK

U2 - 10.2174/156652308785160638

DO - 10.2174/156652308785160638

M3 - Article

VL - 8

SP - 273

EP - 286

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 4

ER -